ClinicalTrials.gg

Program

eltrombopag

Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.

Furthest: phase 4, since Jan 7, 201049 company-led studies, 3 open or runningNext primary completion: Apr 22, 2033 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline290 open or runningphase 4since Jan 7, 2010Feb 1, 2005none ahead
Novartis182 open or runningphase 4since Oct 4, 2013Jul 10, 2006Apr 22, 2033phase 2 · NCT07660172
Bristol-Myers Squibb10 open or runningphase 1since Jun 20, 2023Jun 20, 2023none ahead
Renata11 open or runningphase 2since Jul 6, 2024Jul 6, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Feb 1, 2005.

  1. Sep 29, 2014Phase 1 study in Liver CirrhosisGlaxoSmithKline · NCT02254434 · 26 enrolled · Mexico
  2. Oct 30, 2014Phase 1 study in Purpura, Thrombocytopenic, IdiopathicGlaxoSmithKline · NCT02281370 · 39 enrolled · United States
  3. Feb 26, 2015Phase 2 study in Anemia, AplasticNovartis · NCT02404025 · 10 enrolled · Japan
  4. Nov 4, 2016Phase 2 study in Anemia, AplasticNovartis · NCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
  5. Jan 12, 2017Phase 2 study in Anemia, AplasticNovartis · NCT03025698 · 51 enrolled · United States, Hong Kong, Portugal and more
  6. May 2, 2018Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT03524612 · 105 enrolled · United States, Austria, Brazil and more
  7. Oct 23, 2018Phase 2 study in Poor Graft FunctionNovartis · NCT03718533 · 10 enrolled · Spain
  8. Jun 13, 2019Phase 2 study in Anemia, AplasticNovartis · NCT03988608 · 20 enrolled · China
  9. Mar 9, 2020Phase 2 study in Anemia, AplasticNovartis · NCT04328727 · 36 enrolled · China, Japan, South Korea and more
  10. Apr 12, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT04346654 · 26 enrolled · Germany
  11. Mar 4, 2021Phase 2 study in Myelodysplastic SyndromesNovartis · NCT04797000 · 36 enrolled · Japan
  12. Jun 20, 2023Bristol-Myers Squibb's first study: phase 1 study in Healthy AdultsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT05924152 · 16 enrolled · United States
  13. Jul 6, 2024Renata's first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to RenataRenata · NCT06531018 · 100 planned · Bangladesh
  14. Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07660172 · 36 planned

Ahead

  1. Apr 22, 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07660172

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
romiplostimruleAmgenphase 438
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 49 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07660172Purpura, Thrombocytopenic, Idiopathic2Not yet recruitingNovartisApr 22, 203336
NCT06531018Purpura, Thrombocytopenic, Idiopathic · Bangladesh2RecruitingRenataAug 31, 2025100
NCT05924152Healthy Adults · United States1CompletedBristol-Myers SquibbAug 9, 202316
NCT04797000Myelodysplastic Syndromes · Japan2Active, not recruitingNovartisApr 26, 202536
NCT04346654Purpura, Thrombocytopenic, Idiopathic · Germany2CompletedNovartisSep 22, 202326
NCT04328727Anemia, Aplastic · China, Japan, South Korea and more2CompletedNovartisJun 10, 202236
NCT03988608Anemia, Aplastic · China2CompletedNovartisJul 16, 202120
NCT03718533Poor Graft Function · Spain2TerminatedNovartisNov 3, 202010
NCT03524612Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Brazil and more2CompletedNovartisOct 22, 2021105
NCT03025698Anemia, Aplastic · United States, Hong Kong, Portugal and more2CompletedNovartisApr 22, 202251
NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more2CompletedNovartisNov 3, 202054
NCT02404025Anemia, Aplastic · Japan2CompletedNovartisJul 5, 201610
NCT02281370Purpura, Thrombocytopenic, Idiopathic · United States1CompletedGlaxoSmithKlineDec 24, 201439
NCT02254434Liver Cirrhosis · Mexico1CompletedGlaxoSmithKlineSep 8, 201426
NCT02158936Thrombocytopenia · United States, Argentina, Australia and more3TerminatedNovartisApr 30, 2016356
NCT02148133Anemia, Aplastic · Japan2CompletedNovartisSep 10, 201521
NCT01957176Thrombocytopenia · Belgium, China, France and more4CompletedNovartisFeb 23, 202222
NCT01890746Leukemia · United States, Australia, Belgium and more2CompletedNovartisMar 13, 2015148
NCT02201290Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedNovartisJul 4, 20179
NCT01762761Purpura · China3CompletedNovartisJun 5, 2014155
NCT01657552Thrombocytopenia · United States1CompletedGlaxoSmithKlineOct 26, 201256
NCT01636778Hepatitis C, Chronic · Japan2CompletedGlaxoSmithKlineMay 201445
NCT01520909Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Czech Republic and more3CompletedGlaxoSmithKlineJan 201492
NCT01440374Thrombocytopenia · United States, Argentina, Belgium and more2CompletedNovartisMar 2015162
NCT01147809Thrombocytopenia · United States, Belgium, Canada and more2CompletedGlaxoSmithKlineJan 2015130
NCT01098487Purpura · United States, Czech Republic, France and more4CompletedGlaxoSmithKlineMay 2014167
NCT01072162Purpura · United States1CompletedGlaxoSmithKlineApr 7, 201040
NCT01055600Thrombocytopenia · United States4WithdrawnGlaxoSmithKlineJul 20140
NCT00996216Hepatitis C · United States, Australia, Canada and more3CompletedGlaxoSmithKlineFeb 201327
NCT00908037Purpura · United States, Canada, France and more2CompletedGlaxoSmithKlineFeb 1, 201482
NCT00903422Myelodysplastic Syndromes · United States, Brazil, Denmark and more1CompletedGlaxoSmithKlineJun 26, 201298
NCT00861601Liver Diseases · Japan2CompletedGlaxoSmithKlineAug 200938
NCT00833378Hepatitis C · United States1CompletedGlaxoSmithKlineMar 11, 200940
NCT00828750Purpura, Thrombocytopenic, Idiopathic · Japan3CompletedGlaxoSmithKlineFeb 201119
NCT00688272Purpura · United Kingdom1CompletedGlaxoSmithKlineSep 25, 200836
NCT00678587Non-alcoholic Fatty Liver Disease · United States, Argentina, Belgium and more3TerminatedGlaxoSmithKlineOct 2009292
NCT00540423Purpura, Thrombocytopenic, Idiopathic · Japan3CompletedGlaxoSmithKlineDec 200823
NCT00529568Hepatitis C, Chronic · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineAug 2011759
NCT00516321Hepatitis C, Chronic · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineApr 2011687
NCT00487968Purpura, Thrombocytopenic, Idiopathic · United States1CompletedGlaxoSmithKline12
NCT00442871Purpura · United States1CompletedGlaxoSmithKlineJan 3, 200829
NCT00424177Purpura · Germany, Russian Federation2CompletedGlaxoSmithKlineAug 200866
NCT00370331Purpura · United States, Austria, Canada and more3CompletedGlaxoSmithKlineJul 2008197
NCT00359463Purpura · United States, Australia, New Zealand1CompletedGlaxoSmithKlineMar 7, 200733
NCT00358540Thrombocytopenia · United States1CompletedGlaxoSmithKlineOct 22, 201018
NCT00351468Purpura · United States, Australia, Austria and more3CompletedNovartisJul 2015302
NCT00110799Hepatitis C, Chronic · United States, France, Germany and more2CompletedGlaxoSmithKlineOct 200675
NCT00102739Purpura · Germany, Greece, Hong Kong and more2CompletedGlaxoSmithKlineJan 200799
NCT00102726Thrombocytopenia · United States, Argentina, Austria and more2CompletedGlaxoSmithKlineFeb 2007183

How it is read

Names in the registry

  • “Eltrombopag”, 19 entries
  • “eltrombopag”, 15 entries
  • “SB497115”, 3 entries
  • “Eltrombopag olamine”, 2 entries
  • “Eltrombopag 25 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.